Effects of agomelatine (25 to 50 mg/day) on circadian rhythms in patients with Major Depressive Disorder. An exploratory 6-week open, flexible dose, international multicentre, non comparative study.

Trial Profile

Effects of agomelatine (25 to 50 mg/day) on circadian rhythms in patients with Major Depressive Disorder. An exploratory 6-week open, flexible dose, international multicentre, non comparative study.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Agomelatine (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors IRIS
  • Most Recent Events

    • 11 Oct 2014 Status changed from recruiting to completed as reported by EudraCT.
    • 28 Apr 2012 Additional trial locations (Austria, Germany) identified as reported by EudraCT.
    • 28 Apr 2012 Actual initiation date 30 Mar 2012 added as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top